Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

8.050 USD +0.300 (+3.87%)
Streaming Delayed Price Updated: 7:12 AM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Actinium Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
- Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and M&A transactions 
From PR Newswire
Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Sciences Conference, which is being held... 
From PR Newswire
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
- TCT conference visibility bolsters strong momentum as SIERRA nears full enrollment following recent positive interim analysis 
From PR Newswire
Actinium Announces Participation in BIO CEO & Investor Digital Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally... 
From PR Newswire
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference,... 
From PR Newswire
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
- Builds the collaboration utilizing Actinium's Antibody Warhead Enabling (AWE) Technology Platform with selected Astellas targeting agents 
From PR Newswire
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
- 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receiving salvage... 
From PR Newswire
Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit
- Dr. Dale Ludwig, Actinium's Chief Scientific & Technology Officer, to participate in a panel discussion on the discovery of new targets in radiotherapy 
From PR Newswire
Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
- 67% overall response rate includes one complete response in patient with TP53 mutation and one partial response reported in patients with poor risk adverse cytogenetics with subtherapeutic dose of... 
From PR Newswire
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that interim data from its ongoing pivotal Phase 3 trial in patients with relapsed or refractory Acute... 
From PR Newswire
Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting
- Lower rates of non-relapse transplant related mortality, sepsis, infections, and mucositis reported in patients receiving Iomab-B compared to patients on the control arm receiving salvage therapies 
From PR Newswire
Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
- 100% remission rate in the third dose cohort of 0.75 μCi/kg of Actimab-A (lintuzumab-225Ac) and standard regimen of CLAG-M 
From PR Newswire
Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
- Two oral presentations on Iomab-B Phase 3 SIERRA trial 
From PR Newswire
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
- Dr. Chen brings over twenty years of clinical research and development experience; including executing global registrational trials in relapsed and refractory AML 
From PR Newswire
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
- Apamistamab CD45 antibody is the basis for lead Phase 3 candidate Iomab-B for targeting conditioning prior to bone marrow transplant and next generation Iomab-ACT targeted conditioning program for... 
From PR Newswire
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
- Dr. Desai has over twenty-five years of hematology and oncology-focused clinical development and medical affairs experience, including the successful launches of targeted therapies, monoclonal... 
From PR Newswire
Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday,... 
From PR Newswire
Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials
- Event to feature Dr. Ehab Atallah, Medical College of Wisconsin, and Dr. Gary Schiller, UCLA Medical Center 
From PR Newswire
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
- 70% of patients achieving remission were MRD-negative with remissions and MRD negativity reported in all dose cohorts 
From PR Newswire
Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
-- Universal rates of BMT and engraftment continue in Phase 3 SIERRA pivotal trial in relapsed/refractory AML for all patients receiving therapeutic dose of Iomab-B 
From PR Newswire
Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
- There were no DLTs in first dose cohort, combination advances to additional dose cohorts in R/R AML patients 
From PR Newswire
Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook
- Multiple milestones expected in the Fourth Quarter from the Company's ARC pipeline including Phase 3 data from the pivotal SIERRA trial for Iomab-B and Actimab-A combination trials with CLAG-M and... 
From PR Newswire
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
Financialnewsmedia.com News Commentary 
From PR Newswire
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
Tags Featured News ATNM News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
-- NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse... 
From PR Newswire
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research... 
From PR Newswire
Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial
- Continued site additions to support enrollment and proof of concept results in 2021 
From PR Newswire
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients
-- Combination trial, led by UCLA Medical Center and Principal Investigator Gary Shiller, MD, supported by mechanistic rationale and demonstrated synergy of combining venetoclax with targeted radiation... 
From PR Newswire
Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin
- Trial results including data from third dose cohort to be presented by year end; 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.